The selective JAK2 inhibitors SAR317461 and AZD1480 have been reported to inhibit GBM proliferation via this pathway [108,109], and combining the approved EGFR inhibitors Erlotinib and Osimertinib with the JAK2 inhibitor AZD1480 induces irreversible apoptosis in GBM [110]. The gene discussed is JAK2; the disease is glioblastoma.